Reassessing Zynerba Pharmaceuticals (NASDAQ:ZYNE) | Seeking Alpha
g260361mmi008.gif
Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside
Form 8-K for Zynerba Pharmaceuticals INC filed 08/09/2022
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba hopes to crack fragile X at last | Evaluate
Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients (NASDAQ:ZYNE) | Seeking Alpha
Zynerba Pharmaceuticals Inc receives guidance from the US Food and Drug Administration on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome
g260361mmi021.gif
Zynerba Pharmaceuticals receives FDA approval for cannabinoid therapies
Zynerba Pharmaceuticals Inc's CBD skin gel Zygel offers a potential goldmine of therapies for Fragile X syndrome, and other conditions
Zygel - Zynerba
Zynerba sinks after total failure in phase 2 cannabidiol trial | Fierce Biotech
Zynerba Synthetic CBD Gel for Epilepsy Proves Safe but Not Effective in FDA Phase 2 Trial – New Cannabis Ventures
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/YST6UFBNEVBAXNOUKDYSHHF4AM.PNG "Synthetic CBD from Main Line biotech gets fast track status from FDA")
Synthetic CBD from Main Line biotech gets fast track status from FDA
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
Shares of Devon-Based Zynerba Pharmaceuticals Surge After Firm Wins Patent
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
